Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03167723 · ClinicalTrials.gov registry record · NA
Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 193
- Enrollment target
NCT03167723 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 193 participants.
The verdict
NCT03167723, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 193 participants
- Enrollment target
Study Summary
Traumatic hemothorax and hemopneumothorax are common diagnoses which are typically treated by placement of a chest tube. 28-32 Fr chest tubes have previously been shown equivalent to 36-40 Fr chest tubes for the non-emergent drainage of hemothorax. A smaller study has found 14 Fr pigtails had less pain than larger tubes but was not powered to compare outcomes. We seek to perform a prospective randomized trial that is adequately powered comparing efficacy of 14 Fr thal tubes to 28 Fr chest tubes for non-emergent drainage of hemothorax and hemopneumothorax. Additionally, we will employ maximal barrier precautions for all chest tube insertions and compare empyema rates to our historical controls.
Interventions
- DEVICE Chest tube placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2021-12-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03167723
The ClinicalTrials.gov registry entry for NCT03167723 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chest tube placement is the first listed.
NCT03167723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03167723 about?
NCT03167723 is a clinical study titled "Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions". Traumatic hemothorax and hemopneumothorax are common diagnoses which are typically treated by placement of a chest tube. 28-32 Fr chest tubes have previously been shown equivalent to 36-40 Fr chest tubes for the non-emergent drainage of hemothorax. A smaller study has found 14 Fr pigtails had less p...
What is the current status of trial NCT03167723?
This trial is currently completed. It is a NA study. The enrollment target is 193 participants. The study started on 2017-05-08. Estimated completion is 2021-12-20.
What interventions are being tested in trial NCT03167723?
The interventions under investigation include: Chest tube placement (DEVICE).
Who is sponsoring clinical trial NCT03167723?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.